Trevi Therapeutics Pre-Tax Profit Margin 2018-2024 | TRVI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Trevi Therapeutics pre-tax profit margin from 2018 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Trevi Therapeutics Pre-Tax Profit Margin 2018-2024 | TRVI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Trevi Therapeutics pre-tax profit margin from 2018 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$149.8B
Vertex Pharmaceuticals (VRTX)	$120.3B
Bristol Myers Squibb (BMY)	$115.2B
Gilead Sciences (GILD)	$110.2B
CSL (CSLLY)	$85.5B
Regeneron Pharmaceuticals (REGN)	$83.7B
GSK (GSK)	$69.8B
Argenex SE (ARGX)	$34B
Alnylam Pharmaceuticals (ALNY)	$30B
BioNTech SE (BNTX)	$24.4B
Biogen (BIIB)	$23B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$15.2B
Incyte (INCY)	$14.8B
Genmab (GMAB)	$13.7B
Insmed (INSM)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.8B
Bio-Techne Corp (TECH)	$10.6B
Sarepta Therapeutics (SRPT)	$10B
Exelixis (EXEL)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.4B
Exact Sciences (EXAS)	$9.2B
Revolution Medicines (RVMD)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.7B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$7.4B
Repligen (RGEN)	$6.9B